PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.

pdx news

PDX Pharma awarded two-year $1.87M phase II SBIR grant from the National Cancer Institute (NCI) for the development of ARAC-02, a novel lung cancer treatment

2/21/2023
read more
PDX Pharma’s ARAC-02 drug candidate has been selected into the Nanotechnology Characterization Lab (NCL)’s collaboration and characterization program.

1/5/2023
read more
PDX Pharma won two Corporate Philanthropy Awards

11/2/2022
read more

PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH

pdx news

PDX Pharma awarded two-year $1.87M phase II SBIR grant from the National Cancer Institute (NCI) for the development of ARAC-02, a novel lung cancer treatment

2/21/2023

PDX Pharma’s ARAC-02 drug candidate has been selected into the Nanotechnology Characterization Lab (NCL)’s collaboration and characterization program.

1/5/2023

PDX Pharma won two Corporate Philanthropy Awards

11/2/2022